NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has exclusively licensed rights to Proteome Sciences’ TMT isobaric mass tag technology, the Cobham, UK-based firm announced yesterday.
Proteome Sciences will manufacture the TMT reagents and Thermo Fisher will market and sell them through its Pierce product line. The TMT patents expire in 2021, and Thermo Fisher has the right to provide third-party commercial licenses for use of any type of isobaric tandem mass tags.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.